The Evidence Dilemma In Genomic Medicine
- 1 November 2008
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 27 (6) , 1600-1611
- https://doi.org/10.1377/hlthaff.27.6.1600
Abstract
An ongoing dilemma in genomic medicine is balancing the need for scientific innovation with appropriate evidence thresholds for moving technology into practice. The current low threshold allows unsubstantiated technologies to enter into practice, with the potential to overwhelm the health system. Alternatively, establishing an excessively high threshold for evidence could slow the integration of genomics into practice and present disincentives for investing in research and development. Also, variable coverage and reimbursement policies can lead to differential access to technology, exacerbating health disparities. There is an urgent need for a collaborative process for appropriate transition of genomic discoveries from research to practice.Keywords
This publication has 21 references indexed in Scilit:
- The Diploid Genome Sequence of an Individual HumanPLoS Biology, 2007
- Translating Pharmacogenomics: Challenges on the Road to the ClinicPLoS Medicine, 2007
- Translation 2 ResearchAmerican Journal of Preventive Medicine, 2007
- Predictive genetic testing for type 2 diabetesBMJ, 2006
- Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’Health Affairs, 2006
- Linking Pharmacogenetics-Based Diagnostics And Drugs For Personalized MedicineHealth Affairs, 2006
- AcknowledgmentsHealth Affairs, 2006
- The NIH RoadmapScience, 2003
- Genomic profiling to promote a healthy lifestyle: not ready for prime timeNature Genetics, 2003
- Medical and Societal Consequences of the Human Genome ProjectNew England Journal of Medicine, 1999